Rates of cancer deaths have declined 22% over the last 2 decades, which amounts to 1.5 million deaths averted, according to the annual cancer statistics report from the American Cancer Society.
Rates of cancer deaths have declined 22% over the last 2 decades, according to the annual cancer statistics report from the American Cancer Society. The 1.5 million cancer deaths averted can be attributed to earlier detection, better screening practices, improved treatments, and lower rates of smoking.
The report, published in CA: A Cancer Journal for Clinicians, is based on the most recent data from the National Cancer Institute and the Centers for Disease Control and Prevention, and mortality figures from the National Center for Health Statistics.
However, not only is cancer still a leading killer, but the improvement has varied across the country with some regions faring far better than others. Southern states showed the lowest decline in mortality rates, while the Northeast region had the greatest improvement.
Read more: http://cbsn.ws/1Bqun5y
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More